Τίτλος:
Clinical utility of18f-fdg pet in neuroendocrine tumors prior to peptide receptor radionuclide therapy: A systematic review and meta-analysis
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The role of18F-FDG PET in patients with variable grades of neuroendocrine tumors (NETs) prior to peptide receptor radionuclide therapy (PRRT) has not been adequately elucidated. We aimed to evaluate the impact of18F-FDG PET status on disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) in neuroendocrine tumor (NET) patients receiving PRRT. We searched the MEDLINE, Embase, Cochrane Library, and Web of Science databases up to July 2020 and used the Newcastle-Ottawa scale (NOS) criteria to assess quality/risk of bias. A total of 5091 articles were screened. In 12 studies, 1492 unique patients with NETs of different origins were included. The DCR for patients with negative18F-FDG PET status prior to PRRT initiation was 91.9%, compared to 74.2% in patients with positive18F-FDG PET status (random effects odds ratio (OR): 4.85; 95% CI: 2.27–10.36). Adjusted analysis of pooled hazard ratios (HRs) confirmed longer PFS and OS in NET patients receiving PRRT with negative18F-FDG PET (random effects HR:2.45; 95%CIs: 1.48–4.04 and HR:2.25; 95% CIs:1.55–3.28, respectively). In conclusion,18F-FDG PET imaging prior to PRRT administration appears to be a useful tool in NET patients to predict tumor response and survival outcomes and a negative FDG uptake of the tumor is associated with prolonged PFS and OS. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Συγγραφείς:
Alevroudis, E.
Spei, M.-E.
Chatziioannou, S.N.
Tsoli, M.
Wallin, G.
Kaltsas, G.
Daskalakis, K.
Περιοδικό:
Blood cancer journal
Λέξεις-κλειδιά:
edotreotide ga 68; fluorodeoxyglucose f 18; somatostatin receptor, cancer control; cancer grading; cancer survival; clinical effectiveness; human; image analysis; neuroendocrine tumor; Newcastle-Ottawa scale; outcome assessment; overall survival; peptide receptor radionuclide therapy; positron emission tomography; progression free survival; protein expression; Review; systematic review; treatment outcome; treatment response
DOI:
10.3390/cancers13081813
